checkAd

    BBS-Bioactive Bone Substitutes Plc  125  0 Kommentare Managers' Transactions – Pekka Jalovaara

    BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 30 November 2023 at 10.00 a.m. (EEST)

    BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

    ____________________________________________

    Person subject to the notification requirement

    Name: Jalovaara, Pekka

    Position: Member of the Board/Deputy member

    Issuer: BBS-Bioactive Bone Substitutes Oyj

    LEI: 743700BYSBP0PCR6N767

    Notification type: INITIAL NOTIFICATION

    Reference number: 743700BYSBP0PCR6N767_20231130065249_5

    ____________________________________________

    Transaction date: 2023-11-28

    Venue not applicable

    Instrument type: SHARE

    ISIN: FI4000260583

    Nature of the transaction: SUBSCRIPTION

    Transaction details

    (1): Volume: 49,995 Unit price: .4 EUR

    Aggregated transactions

    (1): Volume: 49,995 Volume weighted average price: .4 EUR


    For more information, please contact:

    Juliusz Rakowski, CEO
    +358 50 448 5132
    juliusz.rakowski@bbs-artebone.fi

    Certified Advisor:
    Nordic Certified Adviser AB,
    +46 70 551 67 29,
    info@certifiedadviser.se


    BBS in brief

    BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

    BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

    More information: www.bbs-artebone.fi





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    BBS-Bioactive Bone Substitutes Plc Managers' Transactions – Pekka Jalovaara BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 30 November 2023 at 10.00 a.m. (EEST) BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara …